

Alexander Egle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7491209/publications.pdf>

Version: 2024-02-01

204
papers

5,089
citations

94433

37
h-index

110387

64
g-index

210
all docs

210
docs citations

210
times ranked

7786
citing authors

#	ARTICLE	IF	CITATIONS
1	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2022, Publish Ahead of Print, .	2.1	0
2	Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agentsâ€”A Prospective Cohort Study of the AGMT Study-Group. <i>Cancers</i> , 2022, 14, 2459.	3.7	4
3	Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 764-765.	9.1	8
4	Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 226-231.	2.1	24
5	RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 1053-1063.	7.2	17
6	Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre study. <i>ESC Heart Failure</i> , 2021, 8, 37-46.	3.1	35
7	Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1). <i>TJ ETQq11100.784334 rgBT</i>		
8	Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. <i>Lancet Haematology</i> , the, 2021, 8, e135-e148.	4.6	32
9	Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence. <i>ESMO Open</i> , 2021, 6, 100012.	4.5	5
10	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies. <i>Cancers</i> , 2021, 13, 650.	3.7	4
11	Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. <i>Supportive Care in Cancer</i> , 2021, 29, 5197-5207.	2.2	6
12	Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburgâ€”a report from the AGMT COVID-19 Registry. <i>GeroScience</i> , 2021, 43, 1877-1897.	4.6	3
13	Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5449.	4.1	3
14	AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL. <i>Cancers</i> , 2021, 13, 2619.	3.7	5
15	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021, 35, 3059-3072.	7.2	40
16	A POLE Splice Site Deletion Detected in a Patient with Biclonal CLL and Prostate Cancer: A Case Report. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9410.	4.1	2
17	Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. <i>Pancreatology</i> , 2021, 21, 1466-1471.	1.1	6
18	Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1131-1136.	1.9	4

#	ARTICLE	IF	CITATIONS
19	The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9555.	4.1	3
20	Protein kinase C- β -dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia. <i>Stem Cells</i> , 2021, 39, 819-830.	3.2	5
21	Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry. <i>Blood</i> , 2021, 138, 1130-1130.	1.4	0
22	A Lower CD4 Count Predicts Most Causes of Death except Cardiovascular Deaths. The Austrian HIV Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12532.	2.6	3
23	The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry - a Prospective Cohort Study By the AGMT Study Group. <i>Blood</i> , 2021, 138, 64-64.	1.4	0
24	Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study). <i>Blood</i> , 2021, 138, 1669-1669.	1.4	0
25	Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry. <i>Blood</i> , 2021, 138, 3387-3387.	1.4	2
26	Lack of Bmf Facilitates the Selection of Highly Responsive B-Cell Receptor Clones in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 1543-1543.	1.4	0
27	Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 170.	4.1	2
28	Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. <i>Leukemia and Lymphoma</i> , 2020, 61, 377-386.	1.3	14
29	Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30 α -positive aggressive lymphomas. <i>European Journal of Haematology</i> , 2020, 104, 251-258.	2.2	12
30	Interdisciplinary Model for Scheduling Post-discharge Cardiopulmonary Care of Patients Following Severe and Critical SARS-CoV-2 (Coronavirus) Infection. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 157.	2.4	0
31	Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 1663.	2.4	7
32	TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 2498-2502.	7.2	2
33	Stromal cell protein kinase C- β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	18
34	The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 609409.	2.8	15
35	Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer. <i>Oncology Letters</i> , 2020, 19, 1551-1558.	1.8	8
36	Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study). <i>Blood</i> , 2020, 136, 29-30.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial). Blood, 2020, 136, 27-29.	1.4	0
38	The Integrin Adaptor Kindlin-3 Is Important for Development and Retention of Marginal Zone B Cells. Blood, 2020, 136, 46-47.	1.4	0
39	Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study. Blood, 2020, 136, 26-26.	1.4	0
40	Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma. Future Oncology, 2019, 15, 109-120.	2.4	39
41	B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion. Blood, 2019, 134, 1717-1729.	1.4	17
42	Ixazomib+Thalidomide+Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. British Journal of Cancer, 2019, 121, 751-757.	6.4	17
43	Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL maintenance trial. Cancer Medicine, 2019, 8, 1401-1405.	2.8	7
44	Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL2 and/or BIM. European Journal of Haematology, 2019, 102, 437-441.	2.2	18
45	C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients. Journal of Clinical Medicine, 2019, 8, 1791.	2.4	9
46	UNMAINTAINED REMISSION AFTER DISCONTINUATION OF KINASE INHIBITOR TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: AN OBSERVATIONAL COHORT. Hematological Oncology, 2019, 37, 218-219.	1.7	1
47	BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF- κ B Nuclear Translocation. Clinical Cancer Research, 2019, 25, 1901-1912.	7.0	23
48	Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. Leukemia, 2019, 33, 957-968.	7.2	22
49	Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2) Tj ETQq1 1 0.784314 rgBT /Overlaid Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02). Blood, 2019, 134, 696-696.	1.4	4
50	Abstract P3-10-07: A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. , 2019, , .		0
51	Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group. Blood, 2019, 134, 3821-3821.	1.4	2
52	BCR-Induced VLA-4 Activation in the TCL1 Transgenic Mouse Model for Chronic Lymphocytic Leukemia. Blood, 2019, 134, 1730-1730.	1.4	0
53	Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. Wiener Klinische Wochenschrift, 2018, 130, 115-125.	1.9	0
54	Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia. Blood, 2018, 131, 1337-1349.	1.4	18

#	ARTICLE	IF	CITATIONS
55	Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. <i>Blood</i> , 2018, 131, 1206-1218.	1.4	39
56	Clonal evolution and heterogeneity in metastatic head and neck cancer—An analysis of the Austrian Study Group of Medical Tumour Therapy study group. <i>European Journal of Cancer</i> , 2018, 93, 69-78.	2.8	25
57	The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. <i>Pharmacogenomics Journal</i> , 2018, 18, 474-479.	2.0	20
58	Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters. <i>PLoS ONE</i> , 2018, 13, e0206688.	2.5	12
59	DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer. <i>Theranostics</i> , 2018, 8, 2278-2288.	10.0	28
60	Remission maintenance treatment options in chronic lymphocytic leukemia. <i>Cancer Treatment Reviews</i> , 2018, 70, 56-66.	7.7	2
61	Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. <i>Annals of Hematology</i> , 2018, 97, 1825-1839.	1.8	6
62	TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. <i>Oncolmmunology</i> , 2018, 7, e1371399.	4.6	55
63	Long-Term Efficacy and Safety of Ropoginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Pegivera Study Results. <i>Blood</i> , 2018, 132, 3030-3030.	1.4	12
64	Deletion of the p53 Target Gene PUMA Prevents Bone Marrow Failure in a Dyskeratosis Congenita Mouse Model. <i>Blood</i> , 2018, 132, 648-648.	1.4	0
65	Milestones in Chronic Lymphocytic Leukemia. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 8-12.	0.5	0
66	Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. <i>Leukemia</i> , 2017, 31, 1117-1122.	7.2	36
67	Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine — A retrospective single center experience. <i>Leukemia Research</i> , 2017, 59, 12-19.	0.8	15
68	Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 141-144.	1.9	3
69	A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. <i>Blood</i> , 2017, 129, 383-385.	1.4	51
70	Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial. <i>Annals of Hematology</i> , 2017, 96, 1155-1162.	1.8	6
71	Update on squamous cell carcinoma of the head and neck. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 220-223.	0.5	22
72	Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy. <i>PLoS ONE</i> , 2017, 12, e0180995.	2.5	15

#	ARTICLE	IF	CITATIONS
73	The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 326-330.	2.0	15
74	Bcl-2 proteins in development, health, and disease of the hematopoietic system. <i>FEBS Journal</i> , 2016, 283, 2779-2810.	4.7	37
75	Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping. <i>Journal of Clinical Oncology</i> , 2016, 34, 2433-2434.	1.6	4
76	A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw089.	0.9	16
77	The AKT 1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2016, 172, 815-819.	2.5	8
78	Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Maintenance randomised trial. <i>Lancet Haematology</i> , 2016, 3, e317-e329.	4.6	42
79	NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. <i>British Journal of Cancer</i> , 2016, 115, 1264-1272.	6.4	27
80	An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2016, 27, vi231.	1.2	1
81	A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. <i>Leukemia</i> , 2016, 30, 929-936.	7.2	200
82	ILK Induction in Lymphoid Organs by a TNF-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2016, 76, 2186-2196.	0.9	13
83	Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. <i>Leukemia</i> , 2016, 30, 570-579.	7.2	102
84	CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model. <i>Leukemia</i> , 2016, 30, 1409-1413.	7.2	15
85	CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells. <i>Oncotarget</i> , 2016, 7, 49459-49469.	1.8	8
86	Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. <i>Oncotarget</i> , 2016, 7, 51494-51502.	1.8	35
87	Time-to-Treatment in Chronic Myelomonocytic Leukemia - a Novel Prediction Model. <i>Blood</i> , 2016, 128, 5547-5547.	1.4	0
88	Ropeginterferon alfa-2b, a novel IFN-2b, induces high response rates with low toxicity in patients with polycythemia vera. <i>Blood</i> , 2015, 126, 1762-1769.	1.4	142
89	Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1501-1508.	4.9	28
90	B cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T cell clonality in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, e307-10.	3.5	10

#	ARTICLE	IF	CITATIONS
91	The significance of pretreatment anemia in the era of IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. <i>European Journal of Haematology</i> , 2015, 95, 538-544.	2.2	29
92	CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. <i>BMC Cancer</i> , 2015, 15, 725.	2.6	12
93	Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer. <i>BMC Cancer</i> , 2015, 15, 996.	2.6	8
94	Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peginterferon α -2b. <i>American Journal of Hematology</i> , 2015, 90, 288-294.	4.1	44
95	Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 38-42.	0.5	1
96	Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. <i>Leukemia and Lymphoma</i> , 2015, 56, 353-360.	1.3	3
97	Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. <i>FEBS Journal</i> , 2015, 282, 834-849.	4.7	53
98	A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and I^2 -microglobulin. <i>British Journal of Haematology</i> , 2015, 168, 239-245.	2.5	69
99	Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the $\text{TCL}1$ transgenic mouse model. <i>British Journal of Haematology</i> , 2015, 170, 515-522.	2.5	38
100	Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Pegivera Stud. <i>Blood</i> , 2015, 126, 1603-1603.	1.4	1
101	CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21. <i>Oncotarget</i> , 2015, 6, 12048-12060.	1.8	18
102	Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Pegivera Study of Ropeginterferon Alfa-2b, a Novel IFN α -2b, in Polycythemia Vera Patient. <i>Blood</i> , 2015, 126, 4056-4056.	1.4	0
103	Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade. <i>Leukemia</i> , 2014, 28, 954-958.	7.2	29
104	Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 115.	3.7	20
105	Kasabach-Merritt phenomenon in hepatic angiosarcoma. <i>British Journal of Haematology</i> , 2014, 167, 716-718.	2.5	7
106	Human immunodeficiency virus type 2 infections in Austria. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 212-216.	1.9	2
107	Pleural decortication of a marginal zone lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1253-1254.	1.8	0
108	Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. <i>Annals of Hematology</i> , 2014, 93, 459-462.	1.8	50

#	ARTICLE	IF	CITATIONS
109	Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2014, 25, 171-176.	1.2	48
110	C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPi score in diffuse large B-cell lymphoma patients. <i>British Journal of Cancer</i> , 2014, 111, 55-60.	6.4	48
111	Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. <i>Haematologica</i> , 2014, 99, 67-69.	3.5	35
112	Old and new news in CLL: "the pathway, stupid!" <i>Blood</i> , 2014, 124, 989-990.	1.4	1
113	How does lenalidomide target the chronic lymphocytic leukemia microenvironment?. <i>Blood</i> , 2014, 124, 2184-2189.	1.4	60
114	Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Maintenance Trial. <i>Blood</i> , 2014, 124, 20-20.	1.4	8
115	Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model. <i>Blood</i> , 2014, 124, 3298-3298.	1.4	0
116	A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. <i>Blood</i> , 2014, 124, 1976-1976.	1.4	2
117	The Transcription Factor IRF4 Is Crucial for CLL Progression and Regulates Survival and Proliferation in a Microenvironment Related Manner. <i>Blood</i> , 2014, 124, 1973-1973.	1.4	0
118	Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study. <i>Blood</i> , 2014, 124, 3177-3177.	1.4	0
119	Spliceosome Mediated RNA Trans-Splicing for Targeting Kappa+ B-Cell Neoplasms. <i>Blood</i> , 2014, 124, 3633-3633.	1.4	0
120	Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014, 124, 77-77.	1.4	0
121	Azacitidine in patients with WHO-defined AML " Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. <i>Journal of Hematology and Oncology</i> , 2013, 6, 32.	17.0	56
122	What's new in Hodgkin's lymphoma: ASH 2012 and more. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 193-196.	0.5	1
123	The role of maintenance strategies in lymphoma and CLL. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 102-108.	0.5	0
124	Therapy with JAK 1/2 inhibitors for myelofibrosis. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 109-113.	0.5	0
125	Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfectd patient. <i>Annals of Hematology</i> , 2013, 92, 1001-1002.	1.8	3
126	Viral infections and their management in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1602-1613.	1.3	32

#	ARTICLE	IF	CITATIONS
127	Protein Kinase C- β -Dependent Activation of NF- κ B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo. <i>Cancer Cell</i> , 2013, 23, 77-92.	16.8	131
128	Bid-ding for mercy: twisted killer in action. <i>Cell Death and Differentiation</i> , 2013, 20, 847-849.	11.2	1
129	Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome. <i>Oncology Letters</i> , 2013, 6, 1756-1758.	1.8	1
130	Mimicking the microenvironment in chronic lymphocytic leukaemia " where does the journey go?. <i>British Journal of Haematology</i> , 2013, 160, 711-714.	2.5	24
131	Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study. <i>Blood</i> , 2013, 122, 4046-4046.	1.4	6
132	Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results. <i>Blood</i> , 2013, 122, 4164-4164.	1.4	8
133	Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level. <i>PLoS ONE</i> , 2013, 8, e74024.	2.5	12
134	Chronic Lymphocytic Leukemia Cells With Trisomy 12 Home To The Bone Marrow In a CXCR4-Independent Manner and Are Prone To Proliferate In Vitro. <i>Blood</i> , 2013, 122, 870-870.	1.4	0
135	The Spiegelmer [®] Nox-A12 Abrogates Homing Of Human CLL Cells To Bone Marrow and Mobilizes Murine CLL Cells In The $\frac{1}{4}$ -TCL1 Transgenic Mouse Model Of CLL. <i>Blood</i> , 2013, 122, 4111-4111.	1.4	6
136	Proteinkinase C- β Inhibitors Mitigate Microenvironment-Mediated Survival Of CLL Cells and Sensitise Malignant B Cells To Cytotoxic Drugs. <i>Blood</i> , 2013, 122, 669-669.	1.4	0
137	Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. <i>Leukemia</i> , 2012, 26, 2508-2516.	7.2	21
138	AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV). <i>Blood</i> , 2012, 120, 175-175.	1.4	4
139	Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity. <i>PLoS ONE</i> , 2012, 7, e30667.	2.5	3
140	KCa3.1 Blockers Inhibit Cell Proliferation in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 3887-3887.	1.4	0
141	T Cell Exhaustion Contributes to Immune Evasion in Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2012, 120, 1773-1773.	1.4	0
142	Protein Kinase C- β Dependent Activation of NF- κ B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B-Cells in Vivo. <i>Blood</i> , 2012, 120, 314-314.	1.4	20
143	BIRC3 but Not BIRC2 mRNA Expression in Chronic Lymphocytic Leukemia Correlates with Disease Progression and Mediates Decreased Fludarabine Sensitivity in Vitro. <i>Blood</i> , 2012, 120, 563-563.	1.4	0
144	Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient. <i>Blood</i> , 2012, 120, 1613-1613.	1.4	2

#	ARTICLE	IF	CITATIONS
145	Raltegravir in pregnancy: a case series presentation. <i>International Journal of STD and AIDS</i> , 2011, 22, 358-360.	1.1	26
146	3.22 Diversity of T-Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S212.	0.4	1
147	Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. <i>Leukemia</i> , 2011, 25, 1452-1458.	7.2	83
148	Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 75-85.	4.2	31
149	Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria. <i>Infection</i> , 2011, 39, 341-352.	4.7	40
150	Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. <i>Cancer</i> , 2011, 117, 2163-2169.	4.1	51
151	Complete Remission of Waldenström Macroglobulinemia With Azacitidine and Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, e696-e698.	1.6	1
152	Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. <i>Blood</i> , 2011, 118, 1715-1715.	1.4	2
153	A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results. <i>Blood</i> , 2011, 118, 292-292.	1.4	7
154	Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells. <i>PLoS ONE</i> , 2011, 6, e23758.	2.5	43
155	Report on Response and Overall Survival of 128 Unselected, Consecutive AML Patients From the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. <i>Blood</i> , 2011, 118, 4266-4266.	1.4	0
156	Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study. <i>Blood</i> , 2011, 118, 1747-1747.	1.4	1
157	Azacitidine Is Feasible and Safe in Patients with MDS and Co-Existing Plasma Cell Dysplasias (PCD) - Report on 9 Patients From the Austrian Azacitidine Registry (AAR). <i>Blood</i> , 2011, 118, 5056-5056.	1.4	0
158	Clonal Diversity of the T Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2011, 118, 803-803.	1.4	0
159	Riding the 2-edged sword. <i>Blood</i> , 2010, 115, 4325-4326.	1.4	1
160	An uncommon cause of anaemia: Sheehan's syndrome. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 717-719.	1.9	4
161	MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer. <i>Journal of Nucleic Acids Investigation</i> , 2010, 1, 14.	0.8	1
162	Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. <i>Genes and Development</i> , 2010, 24, 1602-1607.	5.9	95

#	ARTICLE	IF	CITATIONS
163	Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. <i>Cell Cycle</i> , 2010, 9, 2836-2840.	2.6	116
164	microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 4191-4197.	1.4	99
165	Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairis AGMT CLL4/Roche ML18434 Study. <i>Blood</i> , 2010, 116, 1380-1380.	1.4	1
166	The BENDALEM CLL 6 AGMT Study – Bendamustine Combined with Alemtuzumab In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis. <i>Blood</i> , 2010, 116, 4633-4633.	1.4	2
167	Deletion of Puma and p21Waf1 In Mice Deactivates p53-Induced Cell Death and Cell Cycle Arrest, but Protects Mice From Irradiation-Induced Lymphomagenesis by a Mechanism Involving Hemopoietic Stem Cell Quiescence. <i>Blood</i> , 2010, 116, 90-90.	1.4	5
168	Molecular and cellular mechanisms of CLL: novel therapeutic approaches. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 405-418.	27.6	129
169	Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals. <i>Antiviral Therapy</i> , 2009, 14, 1189-1193.	1.0	14
170	PKC δ^2 is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC δ^2 as a therapeutic target in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 2791-2794.	1.4	84
171	The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis.. <i>Blood</i> , 2009, 114, 3453-3453.	1.4	9
172	The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia.. <i>Blood</i> , 2009, 114, 1238-1238.	1.4	0
173	Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights. <i>Discovery Medicine</i> , 2009, 8, 157-64.	0.5	2
174	Bim and Bmf in tissue homeostasis and malignant disease. <i>Oncogene</i> , 2008, 27, S41-S52.	5.9	109
175	Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairis Study. <i>Blood</i> , 2008, 112, 3175-3175.	1.4	17
176	T Cell Dynamics during the Pretumor and Tumor Phase in the Murine Tc1 Transgenic Chronic Lymphocytic Leukemia Model. <i>Blood</i> , 2008, 112, 3145-3145.	1.4	0
177	Planned First Efficacy and Safety Analysis of De-Intensified Induction with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairis Study.. <i>Blood</i> , 2007, 110, 2045-2045.	1.4	0
178	Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. <i>Blood</i> , 2006, 108, 2950-2956.	1.4	31
179	Planned First Safety and Efficacy Analysis of Oral Fludarabine Combined with Subcutaneous Alemtuzumab in 2nd Line Therapy of B-Chronic Lymphocytic Leukaemia (B-CLL): The FLUSALEM Study.. <i>Blood</i> , 2006, 108, 4990-4990.	1.4	2
180	The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial. <i>Haematologica</i> , 2006, 91, 1291-3.	3.5	3

#	ARTICLE	IF	CITATIONS
181	Subversion of the Bcl-2 Life/Death Switch in Cancer Development and Therapy. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 469-477.	1.1	26
182	Expression Levels of CD38 in Tumor Cells and T-Cells Are of Prognostic Value in B-CLL. Blood, 2005, 106, 1189-1189.	1.4	12
183	Bim is a suppressor of Myc-induced mouse B cell leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6164-6169.	7.1	444
184	VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood, 2004, 103, 2276-2283.	1.4	193
185	TNF cytokine family: More BAFF-ling complexities. Current Biology, 2001, 11, R1013-R1016.	3.9	21
186	Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood, 2000, 95, 610-618.	1.4	111
187	Analysis of Bcl-2 Protein Expression in Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 2000, 113, 219-229.	0.7	44
188	Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood, 2000, 95, 610-8.	1.4	46
189	Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity. British Journal of Haematology, 1998, 102, 1069-1080.	2.5	13
190	On the Role and Significance of Fas (Apo-1/CD95) Ligand (FasL) Expression in Immune Privileged Tissues and Cancer Cells Using Multiple Myeloma as a Model*. Leukemia and Lymphoma, 1998, 31, 477-490.	1.3	28
191	Differential Sensitivity of CD4+ and CD8+ T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand+ Tumor Cells in B Chronic Lymphocytic Leukemia. Blood, 1998, 91, 4273-4281.	1.4	100
192	Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood, 1998, 91, 4273-81.	1.4	35
193	The interleukin 1 β -converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells. FEBS Letters, 1997, 402, 36-40.	2.8	35
194	Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-Induced Suppression of Immune Surveillance. Blood, 1997, 90, 12-20.	1.4	129
195	Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. British Journal of Haematology, 1997, 97, 418-428.	2.5	39
196	Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-Induced Suppression of Immune Surveillance. Blood, 1997, 90, 12-20.	1.4	20
197	Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood, 1997, 90, 12-20.	1.4	43
198	Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Research, 1997, 57, 3331-4.	0.9	134

#	ARTICLE	IF	CITATIONS
199	Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon- γ . European Journal of Immunology, 1996, 26, 3119-3126.	2.9	70
200	Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies. , 1996, 65, 498-505.		23
201	2-Deoxy-2-fluorodeoxycytidine (Gemcitabine) Induces Apoptosis in Myeloma Cell Lines Resistant to Steroids and 2-Chlorodeoxyadenosine (2CdA). Stem Cells, 1996, 14, 351-362.	3.2	22
202	IL-10 serum levels in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 1996, 94, 211-2.	2.5	6
203	B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance. International Journal of Cancer, 1991, 47, 870-874.	5.1	28
204	Inhibition of cell proliferation, protein kinase C, and phorbol ester-induced fos expression by the dihydropyridine derivative B859-35. Cancer Research, 1991, 51, 5821-5.	0.9	21